Literature DB >> 29180331

[Effects of luteinizing hormone supplementation on outcomes of in vitro fertilization and embryo transfer in patients undergoing GnRH-agonist long protocol].

Yu Deng1, Min-Na Yin, Pei-Ling Liang, Zhi-Heng Chen, Ling Sun.   

Abstract

OBJECTIVE: To compare the clinical outcomes of in vitro fertilization and embryo transfer (IVF-ET) among patients in different conditions receiving luteinizing hormone supplementation in GnRH-agonist long protocol.
METHODS: Between June, 2010 and December, 2015, 671 IVF-ET cycles with GnRH-agonist long protocol were performed at our center. These cycles were divided into group A with FSH only and group B with FSH and recombinant luteinizing hormone (r-LH) supplementation, and each group was divided into 4 subgroups according to age (<35 or ≥35) and the LH level on the initial day (<1.0 U/L or ≥1.0 U/L). The effects of LH supplementation on the clinical pregnancy rate and implantation rate were compared among different subgroups.
RESULTS: No statistical significances were found between groups A and B in age, body mass index (BMI), basal FSH, basal LH, basal E2, Gn dosage, Gn day, LH on HCG day, E2 on HCG day, P on HCG day, number of oocytes, fertilization rate, available embryo rate or good quality embryo rate per oocyte, but the endometrium thickness on HCG day differed significantly between the two groups. In women below 35 years of age with a LH level on HCG day over 1.0 U/L, r-LH supplementation resulted in a clinical pregnancy rate of 60%, significantly lower than the rate of 79.55% in women without r-LH supplementation (P<0.05). In women over 35 years with a LH level below 1.0 U/L, r-LH supplementation resulted in an implantation rate of 44.74%, as compared with 24.74% in women without r-LH supplementation (P<0.05).
CONCLUSION: In the long protocol, LH supplementation does not improve the oocyte number, fertilization rate, or good quality embryo per oocyte, and does not bring benefits to women below 35 years with a low LH level (<1.0 U/L) or those over 35 years with normal LH level (≥1.0 U/L) after GnRH-agonist administration. But for women over 35 years with low LH levels, r-LH supplementation may improve the clinical pregnancy rate and implantation rate of IVF-ET cycles.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29180331      PMCID: PMC6779645     

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  24 in total

1.  Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence.

Authors:  Jan Tesarik; Carmen Mendoza
Journal:  Hum Reprod       Date:  2002-12       Impact factor: 6.918

Review 2.  To add or not to add LH: consideration of LH concentration changes in individual patients.

Authors:  Shahar Kol
Journal:  Reprod Biomed Online       Date:  2005-12       Impact factor: 3.828

Review 3.  Use of recombinant luteinizing hormone for controlled ovarian hyperstimulation in infertile patients.

Authors:  Mônica C S Maia; Mário S Approbato; Tatiana M da Silva; Eliamar A B Fleury; Eliane G M Sanchez; Reinaldo S A Sasaki
Journal:  JBRA Assist Reprod       Date:  2016-05-01

4.  Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.

Authors:  T E König; L E E van der Houwen; A Overbeek; M L Hendriks; S N Beutler-Beemsterboer; W K H Kuchenbecker; C N M Renckens; R E Bernardus; R Schats; R Homburg; P G A Hompes; C B Lambalk
Journal:  Hum Reprod       Date:  2013-07-09       Impact factor: 6.918

Review 5.  Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy: an Asian perspective.

Authors:  Peng Cheang Wong; Jie Qiao; Clement Ho; Gottumukkala A Ramaraju; Budi Wiweko; Yuji Takehara; Prashant V Nadkarni; Li-Chang Cheng; Hsin-Fu Chen; Somchai Suwajanakorn; Thi Ngoc Lan Vuong
Journal:  Reprod Biomed Online       Date:  2011-04-03       Impact factor: 3.828

6.  Randomized trial comparing luteinizing hormone supplementation timing strategies in older women undergoing ovarian stimulation.

Authors:  Hermann M Behre; Colin M Howles; Salvatore Longobardi
Journal:  Reprod Biomed Online       Date:  2015-06-15       Impact factor: 3.828

7.  Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis.

Authors:  Ernesto Bosch; Elena Labarta; Juana Crespo; Carlos Simón; José Remohí; Antonio Pellicer
Journal:  Fertil Steril       Date:  2010-11-10       Impact factor: 7.329

8.  LH supplementation in down-regulated women undergoing assisted reproduction with baseline low serum LH levels.

Authors:  Antonio Pezzuto; Bruno Ferrari; Francesco Coppola; Giovanni Battista Nardelli
Journal:  Gynecol Endocrinol       Date:  2010-02       Impact factor: 2.260

9.  The ratio of late-follicular to mid-follicular phase LH concentrations efficiently predicts ART outcomes in women undergoing ART treatment with GnRH-agonist long protocol and stimulation with recombinant FSH.

Authors:  Koji Nakagawa; Shirei Ohgi; Akira Nakashima; Takashi Horikawa; Rikikazu Sugiyama; Hidekazu Saito
Journal:  J Assist Reprod Genet       Date:  2008-08-28       Impact factor: 3.412

10.  Anovulatory Patients Demonstrate a Sharp Decline in LH Levels upon GnRH Antagonist Administration during IVF Cycles.

Authors:  Linoy Segal; Ofer Fainaru; Shahar Kol
Journal:  Rambam Maimonides Med J       Date:  2017-04-28
View more
  1 in total

1.  Comparison between cycles of the same patients when using recombinant luteinizing hormone + recombinant follicle stimulating hormone (rFSH), human menopausal gonadotropin + rFSH and rFSH only.

Authors:  Ahter Tanay Tayyar; Semra Kahraman
Journal:  Arch Med Sci       Date:  2018-01-08       Impact factor: 3.318

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.